510(k) Summary PRYM MEDICAL Ltd. SansibarTM CPAP System 510(k) Number K DOSSE

Submitter's Name:

PRYM MEDICAL Ltd. 12 Hamada Street Beit Hatamar Rehovot 76703, Israel

Tel: 972-8-931-6450 Fax: 972-8-931-6470

Contact Person:

Shoshana Friedman, RAC Push-Med Ltd. 117, Ahuza St., Ra'ananna 43373, Israel

Tel: 972-9-7718130 Fax: 972-9-7718131

Trade Name:

Sansibar™ CPAP System

Classification Name:

Ventilator, Non-Continuous

Classification:

Non-continuous ventilators are II (Product Code BZD).

Predicate Device:

The Sansibar™ CPAP System is substantially equivalent to the Aria CPAP System (Respironics, Inc.) Cleared under K953341.

Performance Standards:

No performance standards have been established for such devices under sections 514 of the Federal Food, Drug, and Cosmetics Act. The SansibarTM CPAP System has been tested for compliance with standards IEC 60601-1 (and amendments), IEC 60601-1-1 (and amendments) and IEC 60601-1-2.

Indication for use:

The SansibarTM CPAP System is indicated for the treatment of adult Obstructive Sleep Apnea (OSA).

Device Description:

- The Sansibar[™] CPAP System is used to assist with patient breathing while sleeping, for the purpose of treating Obstructive Sleep Apnea (OSA). This is by the delivery of Continuous Positive Airway Pressure between 4 and 20 cmH₂O to prevent airway obstruction.

The SansibarTM CPAP System is powered by input voltage 85 to 265 VAC, 50/60Hz. The blower motor provides positive air pressure, which can be adjusted as prescribed by a physician. The blower speed is directly related to air pressure, and is controlled by software. An air filter is located at the back of the device to keep the air clean of dust and other small particles.

The SansibarTM CPAP System has two main user accessible controls, on/off and ramp time, and three multifunctional control keys for menu navigation and user settings. The pressure setting is set by prescription and is locked-out from the end user's reach. The device is designed for use with a remote control and a remote signal interface. It uses a microcontroller to set the various control parameters, turn features on and off, and view the set parameters.

Substantial Equivalence:

Based on a series of safety and performance testing, Prym Medical Ltd. believes that the SansibarTM CPAP System is substantially equivalent to the predicate device cited above without raising new safety and/or effectiveness issues.



AUG 1 5 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Prym Medical, Ltd. c/o Ms. Shoshana Friedman Push-Med Ltd. 117, Ahuza Street, Ra'ananna 43373 ISRAEL

Re: K000888

Sansibar™ CPAP System
Product Code: 73 BZD
Dated: June 4, 2000
Received: July 6, 2000

Dear Ms. Friedman:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Ms. Shoshana Friedman

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

James E. Dillard III

Director

Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k) Number (if	known):	2000 888	
Device Name:	Sansibar™ CPA	P System	
Indications for Us	e:		
	ar ^{тм} CPAP Sy Sleep Apnea (for the treatment of adult
-	·		
	foi	Division Sign-Off)	Ulkna
	i	Division of Cardiovasc and Neurological Devi 510(k) Number	_
		IIS LINE -CONTINUE UH, Office of Device Ev	ON ANOTHER PAGE IF NEEDED)
•	Concurrence of CDF	tri, Office of Device Ev	aluation (ODE)
Prescription Use	V 09)	OR	Over the Counter Use